NUVB
Nuvation Bio IncNYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.64B
P/E Ratio
—
EPS
$-0.43
Beta
1.52
52W High
$9.75
52W Low
$1.57
50-Day MA
$4.59
200-Day MA
$5.12
Dividend Yield
—
Profit Margin
-102.10%
Forward P/E
—
PEG Ratio
—
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $143.05M |
| Gross Profit (TTM) | $129.85M |
| EBITDA | $-148.21M |
| Operating Margin | 4.66% |
| Return on Equity | -39.50% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $0.42 |
| Book Value | $0.88 |
| Price-to-Book | 5.14 |
| Price-to-Sales (TTM) | 11.49 |
| EV/Revenue | 8.16 |
| EV/EBITDA | 2.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2599.00% |
| Shares Outstanding | $347.20M |
| Float | $237.62M |
| % Insiders | 18.59% |
| % Institutions | 64.84% |
Historical Volatility
HV 10-Day
68.63%
HV 20-Day
70.45%
HV 30-Day
61.25%
HV 60-Day
81.41%
HV Rank
13.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.33 target)
2
Strong Buy7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026